When Adult Lead-In Trials Are Not An Option: Ethical & Regulatory Considerations For Pediatric Gene Therapy

By Raffaella Hart and Linda Reuter, BRANY

Pediatric gene therapy programs often face a development reality that traditional clinical pathways were never designed to support. When diseases manifest early and do not persist into adulthood, sponsors cannot rely on adult lead-in trials to establish safety and dosing. Children become the first — and only — study population, triggering a distinct regulatory and ethical framework that introduces new constraints on trial design.

Federal regulations governing pediatric research impose stricter risk thresholds, require careful assessment of direct benefit, and shape everything from protocol structure to consent requirements. Study elements that are routine in adult trials — such as placebo arms or research-only procedures — may be unapprovable in pediatric populations, creating downstream delays if these issues surface late. The result is often costly protocol redesign at the IRB stage.

A proactive approach can reduce these risks. Early regulatory analysis, clear separation of research procedures from standard care, thoughtful assent planning, and early IRB engagement help sponsors design trials that are both approvable and feasible. For gene therapies targeting pediatric-onset conditions, understanding these requirements early is not optional — it is central to development strategy.